On July 4, the Government of the Republic of Armenia approved a program for reimbursing expenses related to the registration and re-registration of medicines. This decision will come into effect on July 5 and will cover the registration of Armenian medicines abroad, registration and re-registration according to EAEU regulations, and registration and re-registration of medicines produced solely for the domestic market that were conducted after January 1, 2024.
According to the program, during 2024, pharmaceutical companies that are residents of the Republic of Armenia have the opportunity to:
- Register 10-20 pharmaceutical products abroad with compensation up to 25 million AMD. For each drug, an amount of 1.25-2.5 million AMD will be provided.
- For registration and re-registration according to EAEU regulations, compensation of 60 million drams will be available. This will cover 45-50 drug registrations, with a maximum of 1.05 million AMD per drug.
- For registration and re-registration of medicines intended only for the domestic market, compensation of 35 million AMD will be provided, allowing for the registration of 60 medicines. The maximum amount provided for each medicine will be 550,000 AMD.
We sincerely hope that this program will alleviate the financial burden on local producers, increase the share of local products in the Armenian market, and boost the export volume of local products.
